» Articles » PMID: 25670053

Patient and Physician Delay in the Diagnosis and Treatment of Non-small Cell Lung Cancer in Turkey

Abstract

Aim: The early diagnosis and treatment of lung cancer are important for the prognosis of patients with lung cancer. This study was undertaken to investigate patient and doctor delays in the diagnosis and treatment of NSCLC and the factors affecting these delays.

Materials And Methods: A total of 1016 patients, including 926 (91.1%) males and 90 (8.9%) females with a mean age of 61.5±10.1 years, were enrolled prospectively in this study between May 2010 and May 2011 from 17 sites in various Turkish provinces.

Results: The patient delay was found to be 49.9±96.9 days, doctor delay was found to be 87.7±99.6 days, and total delay was found to be 131.3±135.2 days. The referral delay was found to be 61.6±127.2 days, diagnostic delay was found to be 20.4±44.5 days, and treatment delay was found to be 24.4±54.9 days. When the major factors responsible for these delays were examined, patient delay was found to be more frequent in workers, while referral delay was found to be more frequent in patients living in villages (p<0.05). We determined that referral delay, doctor delay, and total delay increased as the number of doctors who were consulted by patients increased (p<0.05). Additionally, we determined that diagnostic and treatment delays were more frequent at the early tumour stages in NSCLC patients (p<0.05).

Discussion: The extended length of patient delay underscores the necessity of educating people about lung cancer. To decrease doctor delay, education is a crucial first step. Additionally, to further reduce the diagnostic and treatment delays of chest specialists, multidisciplinary management and algorithms must be used regularly.

Citing Articles

Evaluating the Time Interval Between Symptoms Onset, Diagnosis, and Therapeutic Intervention in Lung Cancer: A Cross-Sectional Study in Southern Iran.

Salehi A, Rezvani A, Fallahi M, Gholamabbas G, Moayedfar M Cancer Rep (Hoboken). 2024; 7(10):e70026.

PMID: 39423347 PMC: 11488750. DOI: 10.1002/cnr2.70026.


Are Turkish pharmaceutical pricing strategies an access barrier to oncology medicines for Türkiye?.

Vural E, Kaskati T, Vural I, Ozalp M, Gumusel B Front Pharmacol. 2024; 15:1364341.

PMID: 38799164 PMC: 11117076. DOI: 10.3389/fphar.2024.1364341.


Factors Associated with the Delay in Seeing a Doctor: Evidence of Chinese Middle-Aged and Older Adults.

Qin S, Ni X, Ding Y J Multidiscip Healthc. 2024; 16:4239-4253.

PMID: 38164460 PMC: 10758318. DOI: 10.2147/JMDH.S443683.


Factors influencing the timeliness of care for patients with lung cancer in Bangladesh.

Ansar A, Lewis V, McDonald C, Liu C, Rahman M BMC Health Serv Res. 2023; 23(1):261.

PMID: 36927788 PMC: 10018894. DOI: 10.1186/s12913-023-09154-8.


1-year mortality in lung cancer in France according to key timepoints of care pathways.

Riviere A, Lecuyer A, Laurent E, Lefebvre C, Lecomte T, Olivier E ERJ Open Res. 2022; 8(4).

PMID: 36451842 PMC: 9703150. DOI: 10.1183/23120541.00157-2022.